Opens in a new tab
Free worldwide shipping
← All research
mTOR & Autophagy Preclinical Study

MTORC1 Regulates Cardiac Function And Myocyte Survival Through 4E-BP1 Inhibition In Mice

Source publication · 2010 · Zhang D, et al.

Research Summary

This study asked whether mTOR activity helps or harms the adult heart. The researchers switched off the Mtor gene only in the heart muscle of adult mice and followed heart structure, function and survival, with and without added pressure stress. They then tested whether also removing 4E-BP1, a protein that mTORC1 normally keeps in check, changed the outcome.

Who Or What Was Studied?

Genetically modified mice in which the Mtor gene could be deleted in heart muscle cells by tamoxifen injection at 8 weeks of age, compared with control mice. Some mice underwent transverse aortic constriction, a surgery that creates pressure overload on the heart. Double-knockout mice lacking both heart mTOR and 4E-BP1 were also studied, along with cultured heart muscle cells.

What Did The Research Show?

  • Mice without heart mTOR developed a dilated, failing heart. Deaths began 4 weeks after tamoxifen, median survival was 6 weeks, and none survived beyond 8 weeks.
  • At 4 weeks, fractional shortening (a measure of pumping) fell to 26.4 ± 6.7% versus 49.2 ± 5.2% in controls, with more heart cell death (apoptosis), fibrosis and damaged mitochondria.
  • Even a partial loss of mTOR blunted the heart’s thickening response to pressure overload and sped up heart failure: 2 weeks after surgery, fractional shortening was 35.5% versus 51.0% in operated controls.
  • Unphosphorylated 4E-BP1 built up in mTOR-deficient hearts. Also removing 4E-BP1 improved survival and brought fractional shortening back to normal at 4 weeks (46.7 ± 4.0%).
  • In cultured heart cells, a form of 4E-BP1 that cannot be switched off increased markers of cell death (cleaved caspases 3 and 9).

Limitations And Interpretation

  • Mouse data, not human.
  • Genetic deletion removes both mTOR complexes (mTORC1 and mTORC2), which is not the same as rapamycin treatment; the authors note that rapamycin has reduced harmful heart remodelling in other rodent studies.
  • The study did not test rapamycin or any ageing outcome, so it says little directly about low-dose rapamycin use.

Summary prepared from the published paper (abstract and full text where accessible). This is not medical advice — always consult the original publication.

Source: publication record ↗